Thea im of this study was to assess whethert riple antiplatelet therapy is superiortodual and monotherapy in attenuating plateletand leucocyte function.Aspirin (A), clopidogrel(C),and dipyridamole(D) were administeredsinglyand in various combinations (A,C,D,AC,AD,CD, ACD), each fortwo weeks (without washout) to 11 healthysubjects and to 11 patients withprevious ischaemic strokei nt wo randomisedm ultiwayc rossover trials.At the endofeach two-week periodplateletaggregation, platelet-leucocyteconjugateformation and leucocyte activation were measured ex vivo blindedt ot reatment.P latelets were stimulated with collagen; additional measurements were made with adenosine diphosphate( ADP), plateleta ctivating factor (PAF), adrenaline and thec ombination of, ADP,PAF and adrenKeywords Aspirin, clopidogrel, dipyridamole, platelets,ischaemicstroke aline.Results show that in the presence of collagen,ACDwas superior to all antagonists or combinations, except AC,inr educing aggregation,p latelet-leucocyte conjugate formation,a nd monocyte activation (all p<0.05).ACD was also morep otent than other treatments, except AC,ininhibiting the aggregation and platelet-monocyte conjugate formation induced by the combination of ADP,PAF and adrenaline.The effects were similar in both volunteersa nd strokep atients. No seriousa dverse events or major bleeding events occurred. Tr iple antiplatelet therapy didnot appear to be moreeffectivethan combined aspirin and clopidogrel in moderating plateletand leucocyte function.Anyadditionalclinical benefit provided by dipyridamole may be throughothermechanisms of action.
Introduction
Antiplatelet agents are nowestablished in secondaryprevention after ischaemic strokea nd transient ischaemic attack ( 1) . Aspirin, clopidogrel and dipyridamoleeach reduce recurrent vascular eventsb ya bout 20% in patients with prior ischaemic cerebrovascular disease (1) (2) (3) . Evidenceisnow accruing thatcombining antiplateleta gents with different modes of action increases their effectiveness in reducing vascularevents. The 'Second European StrokeP revention Study' (ESPS-2) showedt hat the relative risk reduction for strokewas doubledwith combined aspirina nd dipyridamole as comparedw ith eithera gent alone (3) .Similarly, the combination of aspirinand clopidogrel wassuperior to aspirin alone in reducing vasculare vents in patients with acute coronarysyndromesinthe 'Clopidogrel in Unstable Angina to Prevent RecurrentE vents' (CURE) trial, and those having percutaneous coronaryi ntervention in the 'Clopidogrel forthe Reduction of Events During Observation' (CREDO) trial (4, 5) . These beneficial findings were in spite of a30% increase in major bleeding events(significant in CURE, non-significant in ESPS-2 and CREDO) as seen in eachtrial.
If twoa ntiplatelet agents offeri mproved prophylaxis, then three agents might be betterstill, providing the bleeding risk does not increase disproportionately. We have previouslyassessedthe pharmacologicaleffects in vitro of combining the threeantiplatelet agents, aspirin, dipyridamole and AR-C69931 (6),onplateleta ggregation, platelet-leucocyte conjugatef ormation and leucocyte activation, processeswhich arethought to be involved in vasculardiseaseprogression (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .AR-C69931, adirect acting P2Y 12 receptor antagonist wasusedinplace of clopidogrel sincet he latter is ap ro-druga nd is ineffective in vitro .Whilst combined aspirina nd AR-C69931 wasa se ffectivea sa ll three agents usedt ogether in inhibiting plateleta ggregation, the formation of platelet-leucocyte conjugates and leucocyte acti-vation were most inhibitedw hen all threea ntiplatelet agents were present (18) . Overall,the findings suggested that the combination of threeantiplatelet agents with different modes of action wassuperior to anysingle agentalone,orpairs of agents, in modifying plateleta ctivity and heterotypic cella dhesion and leucocyte activation.
Thepurpose of the present randomised crossovertrial wasto comparethe effects of aspirin, clopidogrel and dipyridamoleadministereds inglya nd in variousc ombinations on plateleta nd leucocyte activation, and platelet-leucocyte conjugation, in normalvolunteersand in patients with aprior historyofischaemic stroke. Theprimary aimwas to assess whether triple antiplatelet therapyw as superior to duala nd mono therapyi na ttenuating collagen-induced activation of platelets, leucocytes, and their conjugation. Collagenwas used as the primary agonist because this is the material thati se xposed following vasculard amage (19, 20) . Other agonists investigated were ADP,adrenaline and PA F, whichw ere studieds inglya nd in combination. These are agents thata re knownt os ynergise to promote plateleta ggregation and also influenceleucocyte function (19) (20) (21) (22) .
Methods Design
Tworandomised, outcome-blinded, multiway,crossovertrials of antiplatelettherapywere performed in normalvolunteersand patients with prior ischaemic stroke (Fig. 1 ). Platelet and leucocyte measureswere performed as previously (18) .
Subjects
The study protocol wasa pprovedb yt he localR esearch Ethics Committee. Allsubjects gave written informed consent and the trials were performed according to the HelsinkiDeclaration and the principlesofGood Clinical Practice. Elevenhealthyvolunteers without anyhistoryofvascular diseasewere recruitedfrom hospitaloruniversity staff or their friends. Elevenstablepatients with ap rior historyo fi schaemic stroke( on clinicala nd neuroimaging criteria)w ithin 5y ears (23) were recruitedf rom the strokeservice at Nottingham City Hospital;each patient wasreceiving aspirinfor vascularprophylaxis. Subjectswere screened clinically and afull blood count and electrocardiogram were obtainedbefore participation. Subjectswere excluded if they: hada historyofcerebral haemorrhage, gastrointestinal bleeding,peptic ulcer,a naemia, thrombocytopenia, anys evere concomitant medical condition, or hypersensitivity or intolerancet oa ny of the study drugs; were taking anticoagulation or anon-steroidal anti-inflammatorydrug; had ablood pressure>180/110 mmHg; or were pregnant or lactating women.
Interventions
All subjects receivedtwo week periods of open-labelaspirin (A, 75mg daily), clopidogrel (C,75mg daily) or modified release dipyridamole( D, 200mg twice daily). No washout periodsw ere used sincethe length of treatment (14 days) exceeded the lifespanofplatelets (~10 days). Thedrugs were giveneithersingly (A, C, or D), in pairs (AC, AD,orCD) or all three together (ACD) in random order.Normal volunteers,but not patients, were also studiedo ff allt herapy. Randomisationw as performed using a computera nd the treatment codesh eldb yt he hospital'sP harmacy to ensureconcealment of allocation. Laboratorytests (see below)w ere assesseda tt he end of each two-weekt reatment phase. Adverse events( headache, gastrointestinal symptoms, rash) were similarlyassessedblindedtotreatment.Subjects who withdrewfrom treatment were replaced to ensurethat complete data were present for each person;l aboratoryd ataf rom withdrawing subjectsare notincludedinthe statisticalanalyses.
Laboratorystudy
Bloodw as collected 1-2h ours following drug ingestion. The subjects were seated for 10-15minutesand blood samples were thencollected, usuallyfrom the rightarm,byvenepuncturewith minimalstasis with a19-gauge needle from an antecubital vein and anticoagulatedw ith hirudin (Rhone-Poulenc-Rorer,U K, final concentration 7.2μΜ). The processing of blood samples wasstarted within 5minutesofvenepuncture. Aliquots (480 μ l) of blood were thens tirred at 1000 rpmi naMulti-Sample Agitator (University of Nottingham,U K) for 2m in at 37 o C. Either2 0 μ lc ollagen (HormC hemie, UK, final concentration 2 μ g/mL), ADP (Sigma, UK, 3 μΜ), PA F( Sigma,1μΜ), adrenaline,( Sigma,U K, 10 μΜ), or the combination of al ow concentration of ADP, PA Fand adrenaline (1μΜ,0.33 μΜ and 3.33 μ Mrespectively) were thenadded and the samples stirred for10min.
Platelet aggregation
Plateleta ggregation wasa ssessedb yc ounting the number of singlep latelets usinga nU ltra-Flo 100 Whole Blood Platelet Counter. Aliquots of 15 μ lofblood were transferred into polypropylene tubescontaining 30 μ lfixing solution (150mMNaCl, 0.16% w/v formaldehyde, 4.6 mM disodium EDTA, 4.5 mM/L Na 2 HPO 4 and 1.6mmol/L K 2 HPO 4 pH 7.4). Platelet aggregation wasdeterminedafter comparisonwith the initialplateletcount.
Platelet-leucocyte conjugate formation andleucocyte CD11b expression
Platelet-leucocytec onjugate formation and leucocyte CD11b expression (a measure of leucocyte activation) were determined by flow cytometry. 100 μ laliquots of the blood were treated with 2.0 ml Erythrolyse solution (Serotec, UK) for 10 min at room temperature. Thesamples were thencentrifuged at 380gfor 10 min and the pellets were washedwith FACSflow(Becton Dickinson, UK), and thenre-centrifuged. Thepellets were finallyresuspendedin100 μ lDulbecco'sPBS containing 10% (v/v) new borncalfserum.A30 μ laliquotwas incubatedat4 o Cfor 30 min in the darkw ith saturating concentrations of anti-CD14:PE (BectonD ickinson) to identifyt he monocytes and antiCD42a:FITC (Serotec)toidentify platelets bound to monocytes In some experiments an irrelevant isotypematchedIgG1:FITC (Serotec)was used fornon-specific membrane immunofluorescence.
Flowcytometry
Platelet-leucocyteconjugatesand leucocyte CD11b expression were quantifiedusing aF ACScan flow cytometer(Becton Dickinson) equippedwith a5Wlaser operating at 15 mW powerand aw avelength of 488 nm, and connected to an AppleM ac G3 computer. Leucocytes were monitored using forward light scattera nd side light scatter and fluorescence.L inear modes were used for light scattera nd logm odes for fluorescence.A totalo f1 0,000 leucocyte eventsw ere recorded per sample. Monocytesw ere differentiatedf rom other leucocytesb yt heir CD14:PEp ositivity.P latelet-leucocyte conjugates are reported as the medianCD42a fluorescence of theleucocyte populations. CD11bexpression is reported as the median CD11b:FITC fluorescence of the leucocyte populations.
Safety
The subjects were monitored for adverse eventse very two weeks.Each of the three antiplateletagents has aknown profile of adverse eventsa nd these were specifically assessed: aspirin maypromotebleeding and gastrointestinal disturbance; clopidogrel can causeb leeding and rash; and dipyridamolemay cause bleeding,headacheand gastrointestinal disturbance.
Statisticalanalysis
The phase I(volunteer) and phaseII(patient) trials assessed the effect on blood cell activity ex vivo of triple antiplatelettherapy (ACD)ascompared with mono and dual treatment using arandomisedmultiwaycrossoverdesign. We did not makemultiple other comparisons, e.g. betweend ual and mono therapies, to minimisethe risk of false positive results (typeIerror).Inthe absenceofexisting published data,aninitial samples size of 12 volunteers and 12 patients waschosen. An interim analysis relating to collageneffectsand blindedtotreatment allocation after 6vol-unteers had beene nrolled (data not shown),s uggestedt hat 10-12 subjects would be requiredineach study (power 0.8, alpha 0.05). Collagenwas chosenasthe primaryplateletagonist since it is keyi nm ediating plateleti nteractions with the damaged vesselwall, as occurs during atherothrombosis. Secondary analysesassessedthe effect of antiplatelettherapyonADP,P AF,adrenaline and combined ADP/PAF/adrenaline activatedc ells. Analyses were alsop erformed comparing sampleso na nd off each drug irrespective of the presenceofany other drug: Aversus no A, Cversus no C, and Dversus no D. Baselinedata, i.e.off allantiplatelet agents, in the volunteer group wasnot included in the statisticalanalyses since therewas no equivalent data for the patients with prior cerebrovasculard isease. Ther esults are expressed as mean(standard deviation). The data were analysed as acrossovertrial using aleastsquares analysis fitting treatment, period and volunteer or patient as fixede ffects. Afixed effect analysis wasusedsincethe numbersofsubjects were small and no missing data were present.Pairwise comparisonsw ere performedfor triple therapyversus allotherdrug. The SAS statistical package (Windows, version 6.12,S AS Institute, Maidenhead,UK) wasused.
Results

Subjects
Atotal 22 subjects were recruited(11 healthysubjects and 11 patients with previous ischaemic stroke).The patients were older and had morevascular risk factors(smoking, hypertension, hyperlipidaemia) than the normal volunteers (Table 1) .P atients were recruitedmedian 2(interquartilerange6,range0.1-21.4) months post ictus.
Effectsofthe various platelet agonists
Stirred blood (saline with no antagonist)produced some platelet aggregation, platelet-monocyte conjugateformation, and monocyte activation, butlittle platelet-neutrophil conjugateformation or neutrophil activation (datanot shown).Adding different platelet agonists to the blood enhancedp lateleta ggregation, platelet-monocyte conjugatef ormation, platelet-neutrophil conjugate formation, monocyte activation, and neutrophil activation. However, adrenaline inhibiteds tirring-induced monocyte activation.
Effectsofthe drug treatment
Non-agonist There wasasimilar patternfor the effects of ACDonplateletand leucocyte parametersb etween healthys ubjects and strokep atients. ACDwas moreeffectivethan A, Dand AD,but not C, AC and CD on inhibitionofplateletaggregation. Overall, ACDhad no greater effect thanm ono or dual therapyo np latelet-mono- cyte,p latelet-neutrophil conjugates and leucocyte activation ( Table 2) .
Collagen stimulation
The results in healthy subjectsa nd strokep atients were qualitatively similar.ACD wassuperior to A, C, D, AD and CD,but not AC,atinhibiting collagen-induced aggregation, platelet-leucocytec onjugation, and monocyte and neutrophil activation (Table 3) .
Other agonists (Figures 2and 3) In secondaryanalyses, ACDwas notapparentlysuperior to the other antiplateletstrategiesininhibiting plateletaggregation or the formation of platelet-monocyte conjugates induced by ADP, PA F, adrenaline,a nd combined ADP/PAF/adrenaline. The one exception wasaggregation in response to combined ADP/PAF/ adrenaline where ACDwas superior to allantiplatelet strategies apart from AC.Additionally, ACDwas notsignificantly different from the other antiplateletapproacheswith respect to for monocyte and neutrophil activation, irrespective of agonist (data not shown).
Individualeffects of antiplatelet agents
In furthera nalyses, the effects of each individual drug were studiedoncollagen-inducedcellactivation. Treatment phasesinvolving aspirin(A, AC,AD, ACD) versusnoaspirin (C, D, CD) had significant effect on platelet aggregation, platelet-leucocyte conjugates and leucocyte activation. Similarly,c lopidogrelbased treatment (C,AC, CD,ACD)reduced platelet aggregation (inv olunteersa nd patients), platelet-leucocyte conjugates( patients), butnot leucocyte activation (volunteers and patients),in comparison with no clopidogrel (A, D, AD). There wasnodifference in these parameters when assessedbydipyridamole status (D,AD, CD,ACD versusA,C,AC) ( Table 4) .
Safety
No serious adverse eventsormajor bleeding episodesoccurred. Treatment with dipyridamole wasa ssociatedw ith headacheo f sufficient intensity sucht hat 4v olunteersa nd 3p atients withdrewf rom the triala nd had to be replaced with news ubjects; their data aree xcludedf rom the above analyses.After 17 subjectshad been recruited, we amended the protocol so thatall subsequent recruits were giveno pen-labeld ipyridamole prior to starting the randomisedt rial; 12 of these did not tolerate the drug, largelyb ecauseo fh eadache, and were excluded from furtherstudy.W edid not use techniquestominimise headache suchasweaning up the doseofdipyridamole to induce tolerance.
Other adverse eventsincludedminor bleeding with aspirinand clopidogrel based therapy. We did not assess whether adverse eventswere modifiedbyinteraction betweendrugs, e.g. whether aspirinm odified dipyridamole headache, in viewo ft he small numbersofsubjects.
Discussion
Increased platelet activation is well-documentedinacutevasculars yndromes ( 7) . Studies have shown thatp lateleta ctivation can lead to the formation of platelet-leucocyte conjugates and (12) 93 (32) 96 (33) 111 (38) 108 (37) DvsnoD 67 (11) 66 (9) 130 (49) 125 (41) 51 (13) 48 (12) 95 (34) 93 (31) 109 (37) 110 (39) A: aspirin; C: clopidogrel;D:dipyridamole;vs: versus.
532 Zhao,etal .: Combined aspirin, clopidogrel and dipyridamole leucocyte activation (8, 9, 12) . Thelatterhas the potentialtosupportt hrombus formation via activation of the coagulation cascade with enhanced thrombin generation and fibrin production (10, 11, (13) (14) (15) (16) (17) . This is the first studyt oa ssess the effectso f combining three antiplateleta gents on plateleta nd leucocyte function ex vivo;p reviouss tudiesh avel imitedt heir comparisons to mono and dual antiplatelettherapy (24) . Our study was neutral since we did not confirmthat triple therapyissuperior to dual or mono therapy, at leastinrespect of the plateletand leucocyte parameters we measured. In particular, ACDw as nots uperior to AC in inhibiting collagen-induced platelet and monocyte activation, and heterotypic cellinteractions.However,ACD wasb ettert han other dual combinations (AD, CD)a nd monotherapy. We chose collagenap riori as the focuso ft his study since it is akey agonist in mediating plateletinteractions with the damaged vesselw all, as occurs during atherothrombosis. ACD wasa lso superior to othert reatments, apartf rom AC,i ni nhibiting plateleta ggregation induced by combined ADP/PAF/ adrenaline. These ex vivo results contrast withour earlier in vitro study where we found the combination of ACDwas superior to alldual and mono preparations, especiallyi ni nhibiting platelet-monocyte and platelet-neutrophil conjugateformation, and monocyte and neutrophil activation (6). Importantly,s imilarl aboratory methodswere used in the twostudies. Twopossibilities mayexplain this discrepancy. First,weusedAR-C69931, adirect acting P2Y 12 receptor antagonist,inour in vitro study sinceclopidogrel is apro-drugand therefore ineffective in vitro .Hence, differentialefficacybetween clopidogrel and AR-C69931might explain the results. Second,t he anti-aggregatoryc apacity of dipyridamole in vitro is concentration dependent and we used 10 μ mol/L in our first study. However, modifiedr eleased ipyridamole, givena s2 00 mg twice daily, has previouslyb een shown to achievem aximall evelso f3-4 μΜ after 4d ayso ft reatment (25) . Hence, reliable anti-aggregation concentrations of dipyridamole maynot be achievedwith conventional dosing, as used in our present trials.
Our data do not necessarilyc onflict with the findings of ESPS-II where the combination of dipyridamole and aspirinoffered superior protection againststrokerecurrence thanusing aspirin or dipyridamole alone,a nd where dipyridamolew as superior to placebo (3). It is increasingly becoming clear that drugs exhibiting vascularprotection are often multimodal in their action. Forexample, statins and angiotensin converting enzyme inhibitors have pleiotropic effects beyond their respective lipid and blood pressure lowering effects (26) , althoughthe relevance of these to their provenrole in vascularprevention (23, 27, 28) remains to be established ( 29) . Dipyridamole appearst oa ct throughanumber of mechanisms: it elevatesintracellular cyclic AMPand cyclic GMPconcentrations via inhibition of types III and Vphosphodiesterasesrespectively, and preventsred celluptakeo fc irculating adenosine,ap lateleta ntagonist (30) (31) (32) (33) .I t has beensuggestedthat oraldipyridamole hasmild hypotensive properties, probablymediated viaits inhibition of typesVphosphodiesterase (34) (35) (36) .Wedid not find that dipyridamole (with or without aspirin and/or clopidogrel)lowered blood pressure (data not shown).Inaddition to its inhibitoryeffectsonphosphodiesterasesa nd adenosine uptake, dipyridamole also appearst o stimulate the production of prostacyclin, inhibit lipid peroxidation and smooth muscle proliferation, and has antioxidant properties (34, 35) . Finally, dipyridamole has mildh ypotensive propertieswhich might explain some of its strokeprotective effects (36) . Recently, the capacity of dipyridamole to inhibit plateletfunction inducedbyATP has beenestablished (37).This is under circumstances in whichl arge amountso fa denosine are formed. This mayb ea ni mportant mechanism of thrombus formation in vivo that, so far, has not beenadequatelyexplored.
The potential downside of using multiple antiplateletagents is that the risk of bleeding is increased. Our studyinvolved treatment phaseso fo nlyt wo weeks duration and definitive statements on the safety of ACDc annot be made.N evertheless, no seriousadverse eventsorepisodes of major bleeding occurred. Dipyridamolew as poorly tolerated in some subjectsl eading to earlyw ithdrawal fromt he trial. We did not performf ormal statisticalc omparisons butt reatment with dipyridamole was associatedwith headache(in some cases severe enoughtolead to withdrawal fromt he study), and clopidogrel with minor bleeding.
These studies involved arelativelysmall number of subjects and we mayhavemissedbiologically important differences between ACDa nd dual therapy. However, several points suggest thatthis is unlikely. First,the use of acrossoverdesign maximised the powerofthe study since each subjectacted as their own control. We could not performasample size calculation before the trials sincethe studies were entirelynovel and there were no availabled ata. Nevertheless, ab lindedc alculation after 6p atients in each study suggested thatb iologically relevant differences would be detectablewith asamplesizeof10-12 subjects per trial. Second,the point estimates for ACDand AC were similarfor most measures(although in some comparisonsACD was non-significantlysuperior to AC)such that apower calculation on the final data suggested that atrial involving at least60pa-tients would be requiredtodetect adifference between ACDand AC.The logistics of the study design would preclude enrolling this number of subjects. Third,wewere able to detect meaningful differences between ACDand non AC treatments. Hence, we believe the studywas largeenough to pick up meaningful differences in cellularfunction.
Our study is also limited in that we could not assess allplateleta nd leucocyte measuresf or logisticalr easons. Earlier studieshaveutilisedothermeasures suchahigh shear tests and platelet activation, e.g.P -selectin ( 24) . It is possible that other non-platelet tests relevant to atherothrombosis might have been altered morebyACD,particularlyones addressing the mechanismsg iven above by whichd ipyridamole mayw ork. For example, dipyridamoleappears to reduce plasma vonWillebrand factor levels suggesting it mayh aveap rotective effect on endothelium (38) .
In conclusion,these data do not supportour original hypothesis, first shown in vitro ,that triple antiplatelettherapymight be superior to dualtherapybased on eitheraspirin and clopidogrel or aspirinand dipyridamole. Nevertheless, triple therapyoffers a potential strategy for the acute treatment and prevention of cerebrovascular disease. We have used this combination in the management of asmall number of complex patients suffering recurrent cerebrovasculare vents on dual therapy, and so farh ave found this approach to be both effectiveand safe (39) . Further trials arewarrantedand we are currentlycomparing triple therapywith aspirinalone (tomaximise our ability to detect potential safety issues, especially major bleeding)intwo phase II randomised controlled trials, one involving patients with acutei schaemic strokea nd the other including patients with prior ischaemic strokeorTIA.
